[go: up one dir, main page]

WO2016137516A1 - Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc - Google Patents

Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc Download PDF

Info

Publication number
WO2016137516A1
WO2016137516A1 PCT/US2015/018153 US2015018153W WO2016137516A1 WO 2016137516 A1 WO2016137516 A1 WO 2016137516A1 US 2015018153 W US2015018153 W US 2015018153W WO 2016137516 A1 WO2016137516 A1 WO 2016137516A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
rosacea
micro
pyrithione zinc
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/018153
Other languages
English (en)
Inventor
Paul SUTICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US2015/018153 priority Critical patent/WO2016137516A1/fr
Publication of WO2016137516A1 publication Critical patent/WO2016137516A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds

Definitions

  • This invention relates to the treatment of Rosacea and skin erythema, in general, and to a rnethod utilizing a topical composition employing pyrithione zinc of different concentrations depending on the severity and extent of user symptoms, in particular.
  • Rosacea is a very common red, acne-like benign skin condi ti on that affects approximately 45 million people worldwide. Its main symptoms include red or pink facial skin, small dilated blood vessels, small red bumps sometimes containing pus, cysts, and pink or irritated eyes. Characteristically involving the central region of the face (mainly the forehead, the cheeks, the chin, and the lower half of the nose), Rosacea is considered a chronic, long-term i ncurable skin condition with periodic ups and downs. Tending to occur more frequently in women, but more severely in men, Rosacea strikes both at potentially all ages. Unfortunately, emotional factors such stress, fear, anxiety and embarrassment have been determined to aggravate the condition.
  • zinc pyrithione is also known by the following chemical names Bis [l-hydroxy-2(lH)-pyridinethionato-0,S] (T- 4) zinc (IUPAC), pyrithione zinc, Zinc bis(2-pyridylthio) ⁇ N ⁇ oxide), Zinc pyridinethione, Zinc 2- pyridinethione-l-oxide, Bis (N-ox.opyridine-2-thionato) zinc (II), ZP, ZnPT, ZnPTO, BOTZ; and under the tradenames Zinc Omadine and Vancide ZP— and also having the empirical formula C 10 H g N r) O S Z n .
  • T- 4 zinc
  • IUPAC IUPAC
  • pyrithione zinc Zinc bis(2-pyridylthio) ⁇ N ⁇ oxide
  • Zinc pyridinethione Zinc 2- pyridinethione-l-oxide
  • Zinc pyrithione is currently regulated as a preservative in rinse-off products (excluding oral hygiene products) in an concentration up to 0.5% in general, and up to 1.0% in hair products. Furthermore, zinc pyrithione is also allowed in a concentration up to 0.1% in leave-on hair products. More recently, it has been approved for use in rinse-off anti-dandruff hair care products in concentration from 1.0% to 2.0%. As such, zinc pyrithione (or pyrithione zinc) is commonly employed in zinc bar soaps or shampoos for treating and preventing itching, flaking and scaling of the scalp caused by dandruff or seborrhea, and available without prescription.
  • a topical application including pyrithione zinc is effective in significantly reducing the redness, flushing and inflammation associated with the chronic, incurable adult acne-like skin condition of Rosacea— and with skin erythema, in general.
  • composition of the invention may comprise al l pharmaceutical forms for administration including solutions, gels, lotions and creams -- as well as ointmenLs, foams, emulsions, micro-emulsions, mi lks, serums, aerosols, sprays, dispersions, micro-capsules and micro-particles thereof.
  • Acceptable carriers for the pyrithione zinc are those suitable for topical applications for the skin, will not cause any safety or toxicity concerns, and will be compatible with the pyrithione zinc.
  • One such earner employed successfully with the pyrithione zinc has been found to be cocoa butter, an edible vegetable fat extracted from the cocoa bean.
  • a ratio of about 3 parts cocoa butter to 1 part pyrithione zinc provided almost optimum results in effectiveness to decrease the erythema resulting from Rosacea. Also devisbie as soaps and cleansing bars, a 1 % concentration of pyrithione zinc ingredient has been approved by the FDA for cover-the-counter sales— and thus more readily obtainable, and at a lesser cost than other prescription medications used to treat these sldn conditions. Effective in most instances of Rosacea, more resistant situations can be resolved by i ncreasing the pyri thione zinc concentrations to 2%, 3% or 4% levels; obtainable, however, only by way of dermatological prescription.
  • composition of the invention with its use of pyrithione zinc can provide similar benefits for treating other skin complaints, conditions and affl ictions— as with antibacterial agents, anti-acne agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, and others.
  • pyrithione zinc such other discreet erythema as acne and sunburn can be effectively reduced as well.
  • the composition of the invention is to be administered topically by a vehicle or carrier medium compatible with application to the skin.
  • a useful regimen would be to a) mix 1 % pyrithione zinc with 3 ml of cocoa butter cream; b) apply it to the area of concern; and c) leave the blended mixture for 2-3 minutes at the area of application.
  • the composition will be seen to be highly effective in reducing the flushness and redness caused by Rosacea.
  • the pyrithione zinc is employed as the sole active agent in the composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc comme principe actif dans une administration appliquée de manière topique sur la peau d'un utilisateur. Le pyrithione de zinc peut être inclus dans une composition sous la forme de solutions, gels, lotions, crèmes, onguents, mousses, émulsions, micro-émulsions, laits, sérums, aérosols, sprays, dispersions, micro-capsules et micro-particules. Une telle composition peut comprendre du pyrithione de zinc et une émulsion de beurre de cacao.
PCT/US2015/018153 2015-02-27 2015-02-27 Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc Ceased WO2016137516A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2015/018153 WO2016137516A1 (fr) 2015-02-27 2015-02-27 Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/018153 WO2016137516A1 (fr) 2015-02-27 2015-02-27 Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc

Publications (1)

Publication Number Publication Date
WO2016137516A1 true WO2016137516A1 (fr) 2016-09-01

Family

ID=56789737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/018153 Ceased WO2016137516A1 (fr) 2015-02-27 2015-02-27 Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc

Country Status (1)

Country Link
WO (1) WO2016137516A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021102072A1 (fr) * 2019-11-19 2021-05-27 Rythera Therapeutics, Inc. Composition et procédé de traitement de la peau

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US20080194662A1 (en) * 2007-02-14 2008-08-14 Audrey Kunin Cleanser composition
US20120070392A1 (en) * 2009-03-31 2012-03-22 Hyun-Kyung Lee Composition for inhibiting erythema caused by ultraviolet radiation containing a dipeptide as active ingredient
US20120207688A1 (en) * 2009-10-28 2012-08-16 Guthery B Eugene Rosacea Topical Skin Treatment Method and Formulation
US8673328B2 (en) * 2010-04-11 2014-03-18 Agnes Mwangi Blomberg Topical skin composition comprising shea butter, jojoba oil, petroleum jelly, stearic acid, magnesium sulfate, zinc oxide, glycerin, and water

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US20080194662A1 (en) * 2007-02-14 2008-08-14 Audrey Kunin Cleanser composition
US20120070392A1 (en) * 2009-03-31 2012-03-22 Hyun-Kyung Lee Composition for inhibiting erythema caused by ultraviolet radiation containing a dipeptide as active ingredient
US20120207688A1 (en) * 2009-10-28 2012-08-16 Guthery B Eugene Rosacea Topical Skin Treatment Method and Formulation
US8673328B2 (en) * 2010-04-11 2014-03-18 Agnes Mwangi Blomberg Topical skin composition comprising shea butter, jojoba oil, petroleum jelly, stearic acid, magnesium sulfate, zinc oxide, glycerin, and water

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021102072A1 (fr) * 2019-11-19 2021-05-27 Rythera Therapeutics, Inc. Composition et procédé de traitement de la peau

Similar Documents

Publication Publication Date Title
Borda et al. Treatment of seborrheic dermatitis: a comprehensive review
CA2188892C (fr) Utilisation d'un sel d'yttrium dans une composition destinee au traitement des peaux sensibles
US20010014342A1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
JPH11501941A (ja) カプサゼピンを含有する局所用組成物
BR112020000033B1 (pt) Composições tópicas compreendendo eritrulose e hidroxiacetofenona, seus usos e método para exterminar e/ou inibir leveduras malassezia e fungos
US5968532A (en) Use of an ethylenediamine derivative in a cosmetic or dermatological composition containing in particular a product having an irritant side effect
RU2140263C1 (ru) Фармацевтическая композиция для лечения покраснений кожи нейрогенного происхождения на основе антагониста вещества р
JP2000038340A (ja) 育毛剤および食品
AU2018382466B2 (en) Propanediol monoacetate mononitrate
EP3781152B1 (fr) Formulations topiques comprenant du strontium et du méthylsulfonylméthane (msm) et leur utilisation pour le traitement de la peau
BR102017003313B1 (pt) Composição anticaspa e método para a prevenção, redução ou tratamento da caspa
WO2016137516A1 (fr) Procédé et composition topique pour le traitement de l'acné rosacée et de l'érythème cutané à l'aide de pyrithione de zinc
US20160199405A1 (en) Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Selenium Sulfide
US20160199384A1 (en) Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Pyrithione Zinc
US9987304B2 (en) Method and topical composition for the treatment of Rosacea and skin erythema using selenium sulfide
Chovatiya et al. Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types
US20170173042A1 (en) Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Pyrithione Zinc
US20180256596A1 (en) Method and topical composition for the treatment of rosacea and skin erythema using pyrithione zinc
US20040170591A1 (en) Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base
US20200330429A1 (en) Method of treating truncal acne with trifarotene
WO2016137513A1 (fr) Procédé et composition pour le traitement de l'acné rosacée et d'un érythème de la peau à l'aide de sulfure de sélénium
Buckley Seborrhoeic Dermatitis (SD)
Piraccini et al. Efficacious and safe management of thick scales, redness and flaky scalp condition using a specific shampoo containing urea, glycolic acid, salicylic acid, icthyol pale and laureth 9
CN115243684B (zh) 毛发生长的刺激
Zelenkova Final Report on the Pilot Trial to Verify the Effects of Activated Piroctone Olamine (Label 100ml) in the Management of Psoriasis and Seborrhoeic Dermatitis in Patients Aged 15 to 60 Years

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15883607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15883607

Country of ref document: EP

Kind code of ref document: A1